Combined analysis of estrogen receptor β-1 and progesterone receptor expression identifies lung cancer patients with poor outcome

Clinical Cancer Research

Volumn 17, Issue 1, 2011, Pages 154-164

  Stabile, Laura P ^a   Dacic, Sanja ^a   Land, Stephanie R ^b   Lenzner, Diana E ^b   Dhir, Rajiv ^a   Acquafondata, Marie ^a   Landreneau, Rodney J ^c   Grandis, Jennifer R ^a   Siegfried, Jill M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 1; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEX DIFFERENCE; SMOKING; THORAX SURGERY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78751521520     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0992     Document Type: Article

References (38)

1. Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor a and b and show biological responses to estrogen. Cancer Res 2002;62:2141-50.
2. Oton AB, Belani C, Cai C, et al. Comparison of survival for non-small cell lung cancer between premenopausal and postmenopausal women: an analysis of the National Surveillance, Epidemiology and End Results (SEER) Database. J Clin Oncol (Meeting Abstr) 2006; 24:7038.
3. Albain KS, Unger JM, Gotay CC, et al. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol (Meeting Abstr) 2007;25:7549.
4. Ross H, Oldham FB, Bandstra B, et al. Serum-free estradiol (E2) levels are prognostic in men with chemotherapy-naïve advanced non-small cell lung cancer and performance status (PS) 2. J Clin Oncol (Meeting Abstr) 2007;25:7683.
5. Rapiti E. Reduced lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Presented at the 32nd CTRC-AACR San Antonio Breast Cancer Symposium; 2009. Abstract 35.
6. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243-51.
7. Hershberger PA, Stabile LP, Kanterewicz B, et al. Estrogen receptor beta (ERb) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol 2009;116:102-9.
8. Wu CT, Chang YL, Shih JY, Lee YCl. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005;130:979-86.
9. Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005; 11:7280-7.
10. Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005;11: 5084-9.
11. Skov BG, Fischer BM, Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 2008;59:88-94.
12. Nose N, Sugio K, Oyamo T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009;27:411-7.
13. Di Nunno L, Larsson LG, Rinehart JJ, Beissner RS. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 2000;124:1467-70.
14. Abe K, Miki Y, Ono K, et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol 2010;41:190-8.
15. Raso MG, Behrens C, Herynk MH, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Can Res 2009; 15:5359-68.
16. Ishibashi H, Suzuki T, Suzuki S, et al. Progesterone receptor in nonsmall cell lung cancer - a potent prognostic factor and possible target for endocrine therapy. Cancer Res 2005;65:6450-8.
17. Su JM, Hsu HK, Chang H, et al. Expression of estrogen and progesterone receptors in non-small cell lung cancer: immunohistochemical study. Anticancer Res 1996;16:3803-6.
18. Weinberg OK, Marquez-Garban DC, Fishbein MC, et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005;65: 11287-91.
19. Mah V, Seligson DB, Li A, et al. Aromatase expression predicts survival in women with early-stage non-small cell lung cancer. Cancer Res 2007;67:10484-90.
20. Coombes RC, Hall E, Gibson LJ, et al. A randomozed trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 35011:1081-92.
21. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005;65:1459-70.
22. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005;70:372-81.
23. Garon EB, Sadeghi S, Kabbinavar FF, et al. Interim safety analysis of a phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstr) 2008;26:19091.
24. Toh CK, Ahmad B, Soong R, et al. Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. J Thorac Oncol 2010;5:17-22.
25. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
26. Ordonez-Moran P, Munoz A. Nuclear receptors: genomic and nongenomic effects converge. Cell Cycle 2009;8:1675-80.
27. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006;130:1796-1802.
28. Dougherty SM, Mazhawidza W, Bohn AR, et al. Gender difference in the activity but not expression of estrogen receptors a and b in human lung adenocarcinoma cells. Endocrine-Related Can 2006; 13:113-34.
29. Nose N, Uramoto H, Iwata T, et al. Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer 2010.[Epub ahead of print].
30. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sc. USA 2004;101:13306-11.
31. Sethi S, Coti M, Lonardo F. Expression of estrogen receptor beta 1, but not estrogen receptor beta 2 or alpha is linked to worse prognosis in stage I adenocarcinoma, in women, in a large epidemiological cohort but not in a smaller, single hospital based series. United States and Canadian Academy of Pathology ; 2010. Abstract 1843.
32. Lamy PJ, Pujol P, Thezenas S, et al. Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res Treat 2002;76:65-71.
33. Slatore CG, Chien JW, Au DH, et al. Lung cancer and hormone replacement therapy: Association in the vitamins and lifestyle study. J Clin Oncol 2010;28:1540-6.
34. Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998;58:392-5.
35. Thorneycroft IH, Stone SC. Radioimmunoassay of serum progesterone in women receiving oral contraceptive steroids. Contraception 1972;5:129-46.
36. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteosome. PNAS 2000; 97:1032-7.
37. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-1 inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endo 2003;17:575-88.
38. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006;61: 140-5.